Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 sotagliflozin in Chinese patients with type 2 diabetes inadequately controlled on metformin ± sulfonylurea
CTR20181102Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sotagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Nov 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20181102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181102.